SunTrust Banks Reiterates “$172.00” Price Target for Alexion Pharmaceuticals (ALXN)

Alexion Pharmaceuticals (NASDAQ:ALXN) has been assigned a $172.00 target price by equities researchers at SunTrust Banks in a research note issued to investors on Monday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. SunTrust Banks’ price objective suggests a potential upside of 58.38% from the stock’s previous close.

Other research analysts have also issued reports about the company. Royal Bank of Canada raised their price target on Alexion Pharmaceuticals to $166.00 in a research report on Tuesday, October 24th. Stifel Nicolaus reduced their price target on Alexion Pharmaceuticals from $165.00 to $159.00 and set a “buy” rating on the stock in a research report on Tuesday, October 24th. Zacks Investment Research upgraded Alexion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $144.00 price target on the stock in a research report on Tuesday, October 31st. Credit Suisse Group restated a “buy” rating and issued a $166.00 price target on shares of Alexion Pharmaceuticals in a research report on Tuesday, December 12th. Finally, Leerink Swann restated a “buy” rating and issued a $169.00 price target on shares of Alexion Pharmaceuticals in a research report on Wednesday, December 6th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and twenty-one have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $152.77.

Alexion Pharmaceuticals (NASDAQ:ALXN) traded up $0.13 during midday trading on Monday, hitting $108.60. The stock had a trading volume of 3,039,200 shares, compared to its average volume of 2,023,806. Alexion Pharmaceuticals has a one year low of $96.18 and a one year high of $149.34. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.10 and a quick ratio of 2.62. The firm has a market cap of $24,260.00, a PE ratio of 55.13, a P/E/G ratio of 0.95 and a beta of 1.16.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported $1.48 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.09 by $0.39. Alexion Pharmaceuticals had a return on equity of 12.94% and a net margin of 12.48%. The business had revenue of $909.70 million for the quarter, compared to analyst estimates of $880.38 million. During the same period last year, the company earned $1.26 EPS. The firm’s revenue was up 9.5% on a year-over-year basis. equities research analysts forecast that Alexion Pharmaceuticals will post 6.25 earnings per share for the current year.

In other news, CFO Paul J. Clancy sold 6,079 shares of the business’s stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $116.31, for a total value of $707,048.49. Following the sale, the chief financial officer now directly owns 95,093 shares in the company, valued at $11,060,266.83. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Ludwig Hantson sold 2,553 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $121.63, for a total value of $310,521.39. Following the completion of the sale, the chief executive officer now owns 36,172 shares in the company, valued at $4,399,600.36. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 28,930 shares of company stock worth $3,378,199. Corporate insiders own 4.35% of the company’s stock.

Several institutional investors have recently modified their holdings of ALXN. Valeo Financial Advisors LLC bought a new stake in shares of Alexion Pharmaceuticals in the third quarter valued at about $147,000. Dupont Capital Management Corp bought a new stake in shares of Alexion Pharmaceuticals in the third quarter valued at about $156,000. BT Investment Management Ltd bought a new stake in shares of Alexion Pharmaceuticals in the third quarter valued at about $165,000. Beacon Investment Advisory Services Inc. bought a new stake in shares of Alexion Pharmaceuticals in the third quarter valued at about $201,000. Finally, Invictus RG bought a new stake in shares of Alexion Pharmaceuticals in the third quarter valued at about $202,000. Institutional investors own 94.01% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this news story can be read at https://www.americanbankingnews.com/2018/02/12/suntrust-banks-reiterates-172-00-price-target-for-alexion-pharmaceuticals-alxn.html.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply